Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Liraglutide is a glucagon-like peptide-1 (GLP-1) mimetic used for the treatment of Type 2 diabetes. Similar to the actions of endogenous GLP-1, liraglutide potentiates the post-prandial release of insulin, inhibits glucagon release and increases satiety. Recent epidemiological studies and clinical trials have suggested that treatment with GLP-1 mimetics may also diminish the risk of cardiovascular disease in diabetic patients. The mechanism responsible for this effect has yet to be determined; however, one possibility is that they might do so by a direct effect on vascular endothelium. Since low grade inflammation of the endothelium is an early event in the pathogenesis of atherosclerotic cardiovascular disease (ASCVD), we determined the effects of liraglutide on inflammation in cultured human aortic endothelial cells (HAECs). Liraglutide reduced the inflammatory responses to TNFα and LPS stimulation, as evidenced by both reduced protein expression of the adhesion molecules VCAM-1 and E-Selectin, and THP-1 monocyte adhesion. This was found to result from increased cell Ca2+ and several molecules sensitive to Ca2+ with known anti inflammatory actions in endothelial cells, including CaMKKβ, CaMKI, AMPK, eNOS and CREB. Treatment of the cells with STO-609, a CaMKK inhibitor, diminished both the activation of AMPK, CaMKI and the inhibition of TNFα and LPS-induced monocyte adhesion by liraglutide. Likewise, expression of an shRNA against AMPK nullified the anti-inflammatory effects of liraglutide. The results indicate that liraglutide exerts a strong anti-inflammatory effect on HAECs. They also demonstrate that this is due to its ability to increase intracellular Ca2+ and activate CAMKKβ, which in turn activates AMPK.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, GLP-1 RAs have an anti-inflammatory effect on endothelial vascular cells through a number of molecular mechanisms, including the activation of adenosine monophosphate-activated protein kinase (AMPK) [75].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have shown that GLP-1 and its analogs have anti-inflammatory properties.”
From The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome (2022) · cites this paper as [106]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results demonstrate that the anti-inflammatory effects of liraglutide in human aortic endothelial cells is dependent on activation of CAMKKβ and AMPK, which are cAMP/Ca2+ signaling pathways [60].”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Liraglutide (100 μM) reduced the mRNA expression of adhesion molecules such as vascular cell adhesion molecule- (VCAM-) 1, ICAM-1, and E-selectin in TNF-α- or LPS-stimulated human aortic endothelial cells and human umbilical vein endothelial cells [60–62].”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [60]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Second, GLP-1RAs encourage initiating anti-inflammatory mechanisms such as the AMP-activated protein kinase (AMPK) pathway, which helps suppress inflammation.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Progress and challenges in translating the biology of atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2011) · Nature · doi:10.1038/nature10146 · Cited by 4,010 · cited 1×
“As recently reviewed, TNFa and LPS stimulated monocyte adhesion to endothelial cells are initiating events in the pathogenesis of atherosclerosis [41].”
BackgroundThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“The cellular signaling mechanisms stimulated by GLP-1R agonists in pancreatic b-cells are known [25], but whether GLP-1R agonists directly induce signaling in endothelial cells that could be cardioprotective is not clear.”
BackgroundGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“It potentiates insulin secretion, blocks glucagon release and increases satiety [1,2], but cannot be used directly as a therapy for Type 2 diabetes due to its short (2 minute) half life.”
BackgroundHawley, S. A., Boudeau, J., Reid, J. L., Mustard, K. J., Udd, L., Mäkelä, T. P., Alessi, D. R., & Hardie, D. G. (2003) · Journal of Biology · doi:10.1186/1475-4924-2-28 · Cited by 1,665
Woods, A., Dickerson, K., Heath, R., Hong, S.-P., Momcilovic, M., Johnstone, S. R., Carlson, M., & Carling, D. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.06.005 · Cited by 1,392 · cited 1×
“STO-609 is a CaMKKa and CaMKKb specific inhibitor that has been used in other studies to inhibit the phosphorylation of AMPK resulting from calcium fluxes [39].”
Creely, S. J., McTernan, P. G., Kusminski, C. M., Fisher, F. M., Da Silva, N. F., Khanolkar, M., Evans, M., Harte, A. L., & Kumar, S. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00302.2006 · Cited by 1,043 · cited 2×
“and LPS [17,18] both of which have been linked to increased cardiovascular disease risk [19] and the induction of inflammatory responses in endothelial cells.”
BackgroundThe Ca2+/Calmodulin-dependent Protein Kinase Kinases Are AMP-activated Protein Kinase Kinases
Hurley, R. L., Anderson, K. A., Franzone, J. M., Kemp, B. E., Means, A. R., & Witters, L. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503824200 · Cited by 1,018 · cited 2×
“There are two primary mechanisms for the activation of AMPK in endothelial cells, one through CaMKKb [53] and the other LKB1 [54].”
BackgroundDrucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · cited 1×
“It potentiates insulin secretion, blocks glucagon release and increases satiety [1,2], but cannot be used directly as a therapy for Type 2 diabetes due to its short (2 minute) half life.”
BackgroundNikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 1×
“GLP-1 mimetic therapy improved global left ventricular (LV) function in patients with acute myocardial infarction and LV dysfunction after successful reperfusions [56], and ischemia in patients with coronary artery disease [57].”
BackgroundVascular Adhesion Molecules in Atherosclerosis
Galkina, E., & Ley, K. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.149179 · Cited by 803
Cited by
Items 101–187 of 187
Xie, Z., Enkhjargal, B., Matei, N., Wu, L., Zhu, Q., Zhang, T., Tang, J., & Zhang, J. H. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.750726 · Cited by 27
Ke, J., Wei, R., Yu, F., Zhang, J., & Hong, T. (2016) · Peptides · doi:10.1016/j.peptides.2016.10.009 · Cited by 27
Shah, H., Morieri, M. L., Marcovina, S. M., Sigal, R. J., Gerstein, H. C., Wagner, M. J., Motsinger‐Reif, A. A., Buse, J. B., Kraft, P. L., Mychaleckyj, J. C., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1638 · Cited by 24
Aguilar-Ballester, M., Hurtado-Genovés, G., Taberner-Cortés, A., Herrero-Cervera, A., Martínez‐Hervás, S., & Navarro, H. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020660 · Cited by 29
Anti-stress effects of the glucagon-like peptide-1 receptor agonist liraglutide in zebrafish
Bertelli, P. R., Mocelin, R., Marcon, M., Sachett, A., Gomez, R., Rosa, A. R., Herrmann, A. P., & Piato, Â. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110388 · Cited by 26
Molecular mechanisms of appetite and obesity: a role for brain AMPK
de Morentin, P. B. M., Urisarri, A., Couce, M. L., & López, M. (2016) · Clinical Science · doi:10.1042/cs20160048 · Cited by 22
Xie, Z., Yang, Z., Tian, D., & Chen, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1618079 · Cited by 22
Ido, Y. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12485 · Cited by 22
Self-citationEffect of liraglutide on dietary lipid‐induced insulin resistance in humans
Koška, J., Lopez, L. K., D’Souza, K. M., Osredkar, T., Deer, J., Kurtz, J., Salbe, A. D., Harman, S. M., & Reaven, P. D. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13037 · Cited by 22
van Eenige, R., Ying, Z., Tramper, N., Wiebing, V., Siraj, Z., de Boer, J. F., Lambooij, J. M., Guigas, B., Qu, H., Coşkun, T., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.016 · Cited by 20
Liraglutide effects on epicardial adipose tissue micro-RNAs and intra-operative glucose control
Iacobellis, G., Goldberger, J. J., Lamelas, J., Martinez, C. A., Sterling, C. M., BODENSTAB, M., & Frasca, D. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.08.019 · Cited by 19
Abdelaziz, A. I., Mantawy, E. M., Gad, A. M., Fawzy, H. M., & Azab, S. S. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.110719 · Cited by 20
Taguchi, K., Bessho, N., Kaneko, N., Okudaira, K., Matsumoto, T., & Kobayashi, T. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172776 · Cited by 20
Wu, L., Liu, X., Wang, L.-X., Wang, Y., Wang, L., Guan, B., Chen, Z., & Liu, L. (2016) · Endocrine · doi:10.1007/s12020-016-1190-4 · Cited by 20
Hardie, D. G. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374145-5.00073-5 · Cited by 21
Mahdy, R. N. E., Nader, M. A., Helal, M. G., Abu-Risha, S. E.-S., & Abdelmageed, M. E. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03631-5 · Cited by 20
“…group, SLZ-treated group, and Dula 50 μg/ kg-injected group, respectively, employing Tukey-Kramer multiple comparisons post hoc test after one-way ANOVA symptoms of UC (Krasner et al. 2014, Anbazhagan et al. 2017b, Hunt et al. 2021), but the underlying mechanism is still not completely understood.”
Aini, K., Fukuda, D., Tanaka, K., Higashikuni, Y., Hirata, Y., Yagi, S., Kusunose, K., Yamada, H., Soeki, T., & Sata, M. (2019) · International Heart Journal · doi:10.1536/ihj.19-117 · Cited by 22
Shadboorestan, A., Tarighi, P., Koosha, M., Faghihi, H., Ghahremani, M. H., & Montazeri, H. (2021) · Drug Research · doi:10.1055/a-1345-7890 · Cited by 20
Ridout, K. K., Syed, S. A., Kao, H., Porton, B., Rozenboym, A. V., Tang, J. E., Fulton, S. L., Perera, T. D., Jackowski, A. P., Kral, J. G., et al. (2021) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2021.07.006 · Cited by 20
“pGLP-1 contributes to glucose homeostasis by enhancing insulin sensitivity (17) and has anti-inflammatory (18,19) and antioxidant-like (20) properties.”
BackgroundDe Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
“Moreover, GLP-1 RAs have an anti-inflammatory effect on endothelial vascular cells through a number of molecular mechanisms, including the activation of adenosine monophosphate-activated protein kinase (AMPK) [75].”
BackgroundPrevention of Vascular Complications in Diabetes Mellitus Patients: Focus on the Arterial Wall
Lunder, M., Janić, M., & Šabović, M. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180206113755 · Cited by 21
Guo, J., Chen, X., Wang, C., Ruan, F., Xiong, Y., Wang, L., Abdel-Razek, O. A., Meng, Q., Shahbazov, R., Cooney, R. N., et al. (2023) · Shock · doi:10.1097/shk.0000000000002285 · Cited by 17
The many pathways driving liver inflammation in MASH
Tilg, H., Adolph, T. E., Romeo, S., & Loomba, R. S. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.02.018 · Cited by 20
Rodríguez, C., Sánchez, A., Medina, J. S., Muñoz, M., Hernández, M., López, M., Rivera, L., Contreras, C., & Prieto, D. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15600 · Cited by 16
“…exerts its vasoprotective effects not only through augmentation of endothelial NO availability but also through its anti-inflammatory effects on endothelial cells by suppressing NF-κB, TNF-α and adhesion molecules, such as VCAM-1 and E-selectin (Hattori et al., 2010; Krasner et al., 2014).”
BackgroundAbu-Nejim, H., & Becker, R. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01350-7 · Cited by 16
“Favorable effects were also demonstrated by Krasner and colleagues [58].”
Fan, W., Zhang, Q., Wang, C., Sun, J., Zhang, J., & Yin, Y. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114390 · Cited by 17
Cardiovascular effects of GLP-1 receptor agonism
Winquist, R. J., & Gribkoff, V. K. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2022.02.005 · Cited by 16
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 22
Sex-Specific Antioxidant and Anti-Inflammatory Protective Effects of AMPK in Cardiovascular Diseases
Strohm, L., Mihaliková, D., Czarnowski, A., Schwaibold, Z., Daiber, A., & Stamm, P. (2025) · Antioxidants · doi:10.3390/antiox14050615 · Cited by 14
Biesenbach, P., Heinsen, L. J., Overgaard, K. S., Andersen, T. R., Auscher, S., & Egstrup, K. (2023) · Cardiovascular Therapeutics · doi:10.1155/2023/5126825 · Cited by 13
Adenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapy
Dutta, D., Kalra, S., & Sharma, M. (2016) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.191007 · Cited by 14
Role of Incretin Hormones in Bowel Diseases
Zietek, T., Waldschmitt, N., & Rath, E. (2017) · Endocrine development · doi:10.1159/000475731 · Cited by 13
Zhao, X., Liu, Y., Wang, D., Li, T., Xu, Z., Li, Z., Bai, X., & Wang, Y.-C. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5515 · Cited by 12
“GLP‑1RAs inhibit TNF‑ α ‑induced NF‑ κ B activation and reduce the expression of adhesion molecules, thereby inhibiting the adhesion of monocytes induced by TNF‑ α and LPS, exerting anti‑inflammatory effects, while reducing vascular endothelial damage (148).”
The protective roles of liraglutide on Kawasaki disease via AMPK/mTOR/NF-κB pathway
Ding, Y., Peng, Y., Wu, H., Huang, Y., Sheng, K., Li, C., Chu, M., Ji, W., & Guo, X. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110028 · Cited by 11
Karakasis, P., Patoulias, D., Giannakoulas, G. A., Sagris, Μ., Theofilis, P., Fragakis, N., & Biondi‐Zoccai, G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216411 · Cited by 13
“…be mediated through the activation of calcium/calmodulin-dependent protein kinase I (CaMKI) and cAMP response element-binding protein (CREB), along with the induction of calcium/calmodulin-dependent protein kinase kinase-β (CaMKK β ) and AMP-activated protein kinase (AMPK) signaling pathways [49].”
BackgroundThe effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults
Nilsson, M. S. D., Bove, K. B., Suhrs, H. E., Hermann, T. S., Madsbad, S., Holst, J. J., Prescott, E., & Zander, M. (2019) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2019.01.004 · Cited by 10
“Studies have indicated a direct and indirect anti-inflammatory effect of GLP-1 [33,34].”
BackgroundMachida, A., Suzuki, K., Nakayama, T., Miyagi, S., Maekawa, Y., Murakami, R., Uematsu, M., Kitaoka, T., & Oishi, A. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.5.15 · Cited by 11
“47,48 The medium was changed every 2 days.”
Role of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients with Chronic Heart Failure
Llongueras-Espí, P., García‐Romero, E., Colet, J. C., & González‐Costello, J. (2025) · Biomolecules · doi:10.3390/biom15091342 · Cited by 11
“GLP-1RAs have been described to improve insulin-sensitivity, which enhances endothelial function, to activate nitric oxide (NO) synthase which produces vasodilatation and reduce VCAM-1 and ICAM-1 expression, mitigating local inflammation [35–37].”
A novel strategy to prepare the precursor peptide of liraglutide
Cheng, N., Yang, L., Dai, N., Hu, Z., Yang, F., Chen, R., Cheng, X., Zhou, J., Huang, Y., & Su, Z. (2017) · Process Biochemistry · doi:10.1016/j.procbio.2017.07.006 · Cited by 10
Baek, C. H., Kim, H., Moon, S. Y., & Yang, W. S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120331 · Cited by 10
Gera, A., Latif, F., Borra, V., Naz, S., Mittal, V., Ayoobkhan, F. S., Kumar, T., Wajid, Z., Deb, N., Prasad, T., et al. (2025) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2025.101638 · Cited by 20
Potential of Glucagon-Like Peptide 1 as a Regulator of Impaired Cholesterol Metabolism in the Brain
Kim, Y., & Song, J. (2020) · Advances in Nutrition · doi:10.1093/advances/nmaa080 · Cited by 9
“Furthermore, the GLP-1 agonist liraglutide downregulated the expression of vascular cell adhesion molecule 1 and E-cadherin in endothelial cells (90), in turn attenuating hypertension and stroke (91).”
BackgroundGLP-1 Signalling as a Therapeutic Avenue in Parkinson’s Disease: A Comprehensive Review
Orozco, M. P., Rivadeneira, V. V., & León-Rojas, J. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412163 · Cited by 8
“GLP-1R agonists can stimulate AMPK activity in neurons and glial cells, via upstream kinases or through CaMKK β activation, which is triggered by calcium influx [90].”
Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss
Sundararaman, L. V., Gouda, D., Kumar, A., Sundararaman, S., & Goudra, B. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061978 · Cited by 7
“The GLP-1 agonist exendin-4 also decreased blood cell infiltration and adhesion in the atherosclerosis model [84–86].”
Central Functions of Glucagon-like Peptide-1: Roles in Energy Regulation and Neuroprotection
McGrath, R. T. (2015) · Journal of Steroids & Hormonal Science · doi:10.4172/2157-7536.1000.152 · Cited by 9
“The cytoprotective and anti-inflammatory effects of GLP-1 have been demonstrated in several cell types, including pancreatic islets and endothelial cells [48-50].”
BackgroundEffects of incretin therapy and bariatric surgery on inflammation in obese patients
Tardio, V., Kellett, S., Bidal-St-Aubin, M., & Tsoukas, M. A. (2018) · Obesity Medicine · doi:10.1016/j.obmed.2018.12.001 · Cited by 9
Huang, X., Jiang, D., Feng, X., & Fang, Z.-M. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176698 · Cited by 6
The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease
Guo, Z. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00609-1 · Cited by 8
“Emerging evidence suggests that GLP-1 exerts direct or indirect effects on vascular endothelium [65, 70, 81, 95, 96] and GLP-1RAs have been shown to play anti-adhesive and anti-inflammatory roles in vascular endothelium [97].”
Xuan, Y., Ding, T.-T., Mao, X.-L., Pang, S., He, R., Qin, L., & Yuan, J. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2351473 · Cited by 6
Epicardial Fat Inflammation and GLP-1/GIP Receptor Analogs: Are we Shifting our Perspective?
Iacobellis, G. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02325-5 · Cited by 5
AMPK-Mediated Multi-Organ Protective Effects of GLP-1 Receptor Agonists
Wang, X., & Wang, L. (2025) · Health and Metabolism · doi:10.53941/hm.2025.100004 · Cited by 7
“Knockdown of AMPK reduced these anti-inflammatory effects [69] .”
The effect of liraglutide, a GLP-1 analog, on indomethacin-induced gastric ulcers in diabetic rats
Arslan, H. E., Tekşen, Y., Özatik, O., & Algın, M. C. (2025) · Acta Cirúrgica Brasileira · doi:10.1590/acb407325 · Cited by 6
“As the biological half-life of GLP-1 is short (2–3 min), it cannot be used as a drug 7,8 .”
GLP-1 Receptor Agonists: From Clinical Success to Mechanistic Insight
Patel, T., Rose, J., Katsurada, K., Yada, T., Koutakis, P., Salomon, J., Patel, K. P., & Alfaidi, M. (2026) · Circulation Research · doi:10.1161/circresaha.126.327683 · Cited by 5
EVOO’s Effects on Incretin Production: Is There a Rationale for a Combination in T2DM Therapy?
Amodeo, S., Mirarchi, L., Seidita, A., Citarrella, R., Licata, A., Soresi, M., Iovanna, J., & Giannitrapani, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710120 · Cited by 5
“Furthermore, stimulation of the GLP-1 receptor reduces the proliferation of vessel smooth muscle cells [39,40] and their possible migration into the plaque and induces the stabilization of the plaque itself [41,42].”
BackgroundPotential Role of GLP-1 Based Therapeutics in Coronary Artery Disease
Xiong, Q., Wang, J., Huang, K., Li, W., & Zhang, L. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2811315 · Cited by 4
“This finding indicates that the activation of CaMKK β and AMPK is correlated with the anti-inflammatory effect of liraglutide in endothelial cells [22].”
BackgroundCrawford, P. A., Rhein, J., Chipman, J. G., Beilman, G. J., Cromarty, R. T., Escandón-Vargas, K., Anderson, J. L., Wieking, G., Johnston, A., Ahmed, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.09.698696 · Cited by 5
Shadboorestan, A., Eftekhari, S., Mottaghi-Dastjerdi, N., Shahparvari, R., Tarighi, P., Jahandar, H., Faghihi, H., & Montazeri, H. (2022) · PubMed Central · doi:10.22038/ijbms.2022.64117.14117 · Cited by 3
“(25) concluded from their study that Lira has anti-inflammatory effects on aortic endothelial progenitor cells due to increased intracellular calcium, leading to increased CaMKKB and AMPK activity.”
BackgroundEtoga, M. C. E., Well, E. A., Choukem, S. P., Dehayem, M. Y., Mendane, F., Boli, A. O., Inna, A. A. H., Mbanya, J. C., & Sobngwi, E. (2023) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2023.131005 · Cited by 3
Intracellular calcium channels: Potential targets for type 2 diabetes mellitus?
Zhu, J.-X., Pan, Z.-N., & Li, D. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i4.98995 · Cited by 5
Molecular and clinical roles of incretin-based drugs in patients with heart failure
Orabi, B., Kaddoura, R., Omar, A. S., Carr, C. S., & Alkhulaifi, A. M. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9702-3 · Cited by 2
Wu, C.-C., Hung, C.-J., Wang, Y., Lin, S., Chen, W., Kuan, Y., Liao, S., Yang, C., & Chen, C. (2020) · Molecules · doi:10.3390/molecules25143229 · Cited by 2
“The elevation of FGF-21 (Figure 4B) and insulin (Figure 4D) secretion in propofol-treated rats was associated with higher GLP-1 secretion (Figure 4F) and increased hepatic ERK1/2 protein phosphorylation (Figure 5C); putative effector of GLP-1/GLP-1R [32,33].”
BackgroundGLP-1 receptor agonism in cardiovascular disease prevention
Saleh, H. (2025) · Asia-Pacific Journal of Pharmacotherapy & Toxicology · doi:10.32948/ajpt.2024.11.22 · Cited by 1
Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists
Tran-Duc, P. N., & Heo, K. (2025) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2025.5.e9 · Cited by 4
Lin, M.-P., Xue, B.-J., & Bai, X. (2026) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-026-10759-7 · Cited by 2
“In line with this, Krasner et al. [32] also showed liraglutide, A GLP-1 analogue, has a strong anti-inflammatory effect in cultured HAECs.”
Nama, L., Abubakar, M., Daksh, R., Goel, G., Gajbhiye, R. L., Kumar, P., Rai, A., Murti, K., Ravichandiran, V., & Kumar, N. (2026) · Journal of Molecular Histology · doi:10.1007/s10735-026-10781-8 · Cited by 1
Zawadzki, M., & Karczewska‐Kupczewska, M. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/8388511 · Cited by 1
“…in HAEC cultures that liraglutide downregulated E-selectin and VCAM-1 expression via increased intracellular Ca 2+ levels, activation of Ca 2+ / calmodulin-dependent protein kinase kinase-β (CaMKK β ), and subsequent AMPK activation—leading to suppression of the inflammatory response [100].”
Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis
Tavaglione, F., & Loomba, R. S. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103023 · Cited by 1
“32 GLP-1 receptor agonism has also been shown to modulate the systemic inflammatory tone via central nervous system pathways, contributing to the suppression of systemic TNF through α 1-adrenergic, δ -opioid, and κ -opioid receptor signaling.”
Glucagon-Like Peptide-1 Is Prognostic of Mortality in Acute Respiratory Failure
Hansell, C. E., Aneis, H., Kitsios, G. D., Bain, W., Zhao, Y., Suber, T. L., Evankovich, J. W., Sharma, L., Ramakrishnan, S. K., Prendergast, N. T., et al. (2025) · Critical Care Explorations · doi:10.1097/cce.0000000000001247 · Cited by 4
The Effects and Treatment of Inflammation on Diabetes Mellitus and Cardiovascular Disease
Hattar, L., Mumtaz, T., Mouhayyar, C. E., Matevossian, A., & Johnstone, M. T. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_10 · Cited by 1
Renin-Angiotensin Aldosterone System Modulation and Cardiovascular-Kidney-Metabolic HealthPreprint
Mochel, J. P. (2024) · Preprints.org · doi:10.20944/preprints202406.2075.v1 · Cited by 1
Glucose dysregulation and its effect on peritoneal dialysis patients
Williams, J. K., Gilchrist, M., & Strain, W. D. (2016) · Journal of Kidney Care · doi:10.12968/jokc.2016.1.2.58
Surgical management of diabetes mellitus: future outlook (part 2)
Sazhin, A. V., Khusyainova, A. I., & Petukhov, V. A. (2017) · Endoscopic Surgery · doi:10.17116/endoskop201723250-60
Surgical management of diabetes mellitus: future outlook (part 3)
Sazhin, A. V., Khusyainova, A. I., & Petukhov, V. A. (2017) · Endoscopic Surgery · doi:10.17116/endoskop201723354-64
“Механизм действия этого препарата основан на подавлении экспрессии молекул адгезии в эндотелиоцитах, снижении степени выраженности ЭД в капиллярах кишечной стенки, повышении синтеза оксида азота и снижении воспалительных ЛПС-опос редованных реакций [88].”
Koshibu, M., Mori, Y., Kushima, H., Hiromura, M., Kohashi, K., Terasaki, M., Osaka, N., Fujikawa, T., Fukui, T., & Hirano, T. (2019) · The Showa University Journal of Medical Sciences · doi:10.15369/sujms.31.115
de Medeiros, M. S., Gallani, J. D. A., & Swiech, J. N. D. (2022) · Research Society and Development · doi:10.33448/rsd-v11i15.36858
Exploring Endothelial Injury Syndromes: Mechanisms, Markers, and Therapeutic Potential
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-7154-5
Evidence-based medical therapy for mitral regurgitation in dogs
Mochel, J. P., Ward, J. L., & Stern, J. A. (2026) · Journal of Veterinary Cardiology · doi:10.1016/j.jvc.2026.04.006
Targeting inflammatory pathways in T2DM: Therapeutic interventions
Ali, S., & Jamous, Y. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33590-7.00003-4
Unconventional Applications of Semaglutide and Tirzepatide: From Oncology to Human Reproduction
Vignera, S. L., & Condorelli, R. A. (2026) · Biomedicines · doi:10.3390/biomedicines14071644 · Cited by 1
“Additionally, these agents reduce systemic and local inflammation through suppression of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α ), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 β ), which can contribute to cancer progression [31,32].”
Semaglutide and the Heart: Focus on Their Love–Hate Relationship
Khan, E., Fernandes, J., Gohel, V., Jain, R., Jayne, W., Peck, C., Shah, T. S., Shah, R. S., LaBarge, J., Ray, S. D., et al. (2026) · Hearts · doi:10.3390/hearts7030022
“Specifically, liraglutide, rather than semaglutide, was demonstrated to increase intracellular calcium in a concentration-dependent manner, so this particular mechanism is being extrapolated to semaglutide from class data and awaits direct confirmation [57].”
Papastathopoulou, N. S., Neri, S., Assirelli, E., D’Amuri, A., Greco, S., Ciaffi, J., & Ursini, F. (2026) · Rheumatology Advances in Practice · doi:10.1093/rap/rkag105
Elsayed, A., Ayoub, W. J., ELSAYED, N., Stephens, J. P., Udongwo, N., Elsayed, Y. A.-E., & Ghali, J. K. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00322-3
“…assays using Western blot quantification of phosphorylated eNOS (p-eNOS Ser1177) and fluorometric NO detection, reducing adhesion molecule expression (ICAM-1, VCAM-1, measured by ELISA and flow cytometry) and monocyte infiltration in both preclinical and early human pharmacodynamic studies [11].”
Arecco, A., Piras, G., Cocchiara, F., Maggi, D. C., & Puddu, A. (2026) · Diabetology · doi:10.3390/diabetology7100187
Advances in weight-loss-independent cardiovascular protective mechanisms of GLP-1 receptor agonists
Ma, J., Feng, X., Xu, W., & Lyu, J. (2026) · Peptides · doi:10.1016/j.peptides.2026.171519
Pan, J., Guo, C., Huang, Q., Zhang, Y., Shen, Y., & Guo, C. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm55884
Berikkhanova, K., Inuwa, I., Sultan, Y., Berikkhanov, N., Rakhimova, S., & Akilzhanova, A. R. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15208190
“In cultured human aortic endothelial cells, liraglutide reduced inflammatory responses and altered calcium-dependent AMPK and eNOS signalling [64].”
Metadata
- Authors
- Krasner, N. M., Ido, Y., Ruderman, N. B., & Cacicedo, J. M.
- Affiliations
- Boston University (US)
- Corresponding author
- Krasner, Nadia M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-05-16
- Volume
- 9
- Issue
- 5
- Pages
- e97554
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4023984
- OpenAlex
- W2008026539
- Cited by
- 186
- References
- 57
- Citations by year
- 2026: 16 · 2025: 21 · 2024: 13 · 2023: 14 · 2022: 12 · 2021: 13 · 2020: 8 · 2019: 22 · 2018: 11 · 2017: 19 · 2016: 18 · 2015: 15 · 2014: 3
- FWCI
- 14.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- American Heart Association
- National Institutes of Health (NHLBI T32, HL068758)
- National Heart, Lung, and Blood Institute (PO1 HL068758, P01HL068758, HL07969, T32HL007969)
- National Institute of Diabetes and Digestive and Kidney Diseases (R24DK094749)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Keywords
- liraglutide, GLP-1 receptor agonists, endothelial inflammation, aortic endothelial cells, intracellular calcium, AMPK, CaMKKβ, CaMKI, endothelial nitric oxide synthase, CREB, TNF-α, lipopolysaccharide, monocyte adhesion, VCAM-1, E-selectin, atherosclerotic cardiovascular disease, type 2 diabetes, cardiovascular risk
- MeSH terms
- Liraglutide, Analysis of Variance, Benzimidazoles, Calcium, Cells, Cultured, Endothelium, Vascular, Humans, Immunoenzyme Techniques, Inflammation, Blotting, Western, RNA Interference, RNA, Small Interfering, Endothelial Cells, Glucagon-Like Peptide 1, Naphthalimides, Calcium-Calmodulin-Dependent Protein Kinase Kinase, Incretins, AMP-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.